Navigation Links
Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Date:4/1/2009

eatment of congestive heart failure. It should only be used for the treatment of hyponatremia in patients with underlying heart failure when the expected benefit of raising serum sodium outweighs the increased risk of adverse events. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. In addition, coadministration of Vaprisol with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritanovir, and indinavir, is contraindicated. Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. Serum sodium, volume, and neurological status must be monitored frequently because Vaprisol potentially can cause overly rapid correction of sodium leading to serious sequelae. The use of Vaprisol in patients with hepatic impairment (including ascites, cirrhosis, or portal hypertension) or renal impairment has not been systematically evaluated. Use caution when administering Vaprisol to these patients. The most common adverse reactions reported were infusion site reactions (incidence of 73% and 63% for 20 mg/day and 40 mg/day respectively) which were also the most common type of adverse reaction leading to discontinuation of Vaprisol. Discontinuations from treatment due to infusion site reactions were more common among Vaprisol-treated patients (3%) than among placebo-treated patients (0%). Other common adverse reactions were headaches (8%, 10%), hypokalemia (22%, 10%), orthostatic hypotension (14%, 6%), and pyrexia (11%, 5%) for Vaprisol 20mg/day and 40mg/day, respectively.(1) For full prescribing information, please visit www.Vaprisol.com.

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc., Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innov
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome And Astellas Announce Regulatory Update
2. FDA Approves Additional Indication for Astellas MYCAMINE(R)
3. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
4. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
5. UPMC Health Plan Launches New Personal Health Record
6. HealthInsuranceFinders.com Launches Video Contest for Young Directors
7. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
8. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
9. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
10. Mannatech Launches Phase One of New Sales and Training Tools
11. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Legislation backed by the ... Local Pharmacies Act of 2014”) championing so-called “any ... undermine the availability of lower cost preferred pharmacy ... over the next 10 years, according to new ... Pharmaceutical Care Management Association (PCMA). , The drugstore ...
(Date:7/22/2014)... guidelines on cholesterol treatment and cardiovascular risk assessment state ... dying from atherosclerotic cardiovascular disease or of having a ... similar risk profile (based on age, smoking history, and ... finding for when and how aggressively to treat high ... of Men,s Health , a peer-reviewed publication from Mary ...
(Date:7/22/2014)... 22, 2014 The Pennsylvania judge ... ) in the Philadelphia Court of Common ... damages in cases alleging the medication caused plaintiffs ... LLP reports. In an Order dated July 18, ... request to certify the matter for an immediate ...
(Date:7/22/2014)... 2014 (HealthDay News) -- One of the largest studies ... disorder has uncovered 83 new sites on chromosomes that ... made by an international team of researchers, now bring ... the disorder to 108. Although these schizophrenia-associated ... test to predict who will or will not develop ...
(Date:7/22/2014)... Bayonne, NJ (PRWEB) July 22, 2014 CarePoint ... been recently elected as the President of the medical staff ... Dr. Levine will serve as President, as voted on by ... interests of the medical staff in relation to the administration ... the needs of physicians and to work to make the ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2
... good judges of affordability, but a new study reveals that ... you think about a larger pool of resources (such as ... your wallet). Through a series of four experiments, researchers ... time. Counting calories" Youre more likely to eat that slice ...
... from the University of California San Francisco has identified ... woman is likely to develop subsequent invasive cancer after ... cancer. The research, published by Cell Press in the ... can be used to determine whether a woman should ...
... GREEN BAY, Wis., Nov. 12 Shopko announced ... position of President and Chief,Merchandising Officer. Jones will ... marketing activities of the regional mass retailer. ... roles in the,department store sector, mid-tier chain stores ...
... Va., Nov. 12 Conservationists and scientists,from around ... and Research Symposium, in Orlando, Florida. The Symposium ... Bailey Center for Elephant,Conservation(R) and the International Elephant ... two day global Conference on Elephant,Tuberculosis Research. The ...
... Health releases nationwide eValue8,findings, SCOTTSDALE, Ariz., ... report of health plan performance released today ... (NBCH), health plans could do a,better job ... enabling,improvements in patient safety, care coordination, consumer ...
... Hazelden Foundation offers Barry McMillen - Nicotine Cessation Expert and ... ... Nov. 12 Using tobacco isn,t just a,habit; it,s an addiction. ... for over 50 years. The same principles,of the Hazelden treatment experience ...
Cached Medicine News:Health News:Big ticket: You'll spend more thinking about your bank account than about your wallet 2Health News:Biomarkers predict risk for invasive breast cancer years before the tumor develops 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 2Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 3Health News:Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation 4Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... EASTON, Mass. , July 22, 2014 ... or the "Company") and Parabase Genomics ("Parabase"), ... entered into a strategic research and development ... the collaboration, PBI will develop a front-end, ... molecular diagnostics and newborn confirmatory testing process. ...
(Date:7/22/2014)... New York , July 22, ... Neue Partnerschaft für umfassenden Schutz von ... in Österreich    Equashield ... von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) für ... , einen Vertriebshändler und Hersteller von ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... 1, 2011 Health Diagnostic Laboratory Inc. (HDL, ... to develop a novel laboratory developed test with ... diagnostic test and surgical therapy solutions for the ... coronary heart disease (CHD) and stroke are responsible ...
... Radiation Therapy Services Holdings, Inc. ("Radiation Therapy") announced ... International, Inc., has acquired Medical Developers, LLC ("MDLLC"), ... treatment facilities in Latin America. The ... of $47.5 million in cash, $16.25 million in ...
Cached Medicine Technology:Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 3Radiation Therapy Services Holdings, Inc. Acquires Medical Developers, LLC 2Radiation Therapy Services Holdings, Inc. Acquires Medical Developers, LLC 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: